Peptides DB
Research-centric peptide and protocol reference hub
Study 8 of 8Carbetocin literatureLancet (London, England)Top journal2026

Prevention of postpartum haemorrhage: from evidence to implementation at scale.

Not reported in abstract.

Read at Lancet (London, England)Add to compare

Where it sits

this study against the rest of the carbetocin corpus
2
Preclinical · this one
3
Observational
0
Open-label
2
Randomised
1
Reviews

Summary and findings

Not reported in abstract.

How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Carbetocin corpus

DDiagnosis and treatment of postpartum haemorrhage: a race against time.Lancet (London, England) · 2026BCarbetocin and oxytocin use in emergency cesarean delivery: a prospective observational study of 24-hour bleeding outcomes.BMC pregnancy and childbirth · 2026 · n=300 · Additional uterotonic use occurred in 24.0% (36/150) of the carbetocin group and 33.3% (50/150) of the oxytocin group (p=0.074).HumanBPrevention and management of postpartum hemorrhage and hypertensive disorders of pregnancy: results from a 31-country rapid assessment.BMC pregnancy and childbirth · 2026 · n=31 · Oxytocin regularly available in public facilities by 77% of countries.HumanACarbetocin in the Prevention of Postpartum Hemorrhage after Vaginal Birth: A Systematic Review and Meta-Analysis.Maternal-fetal medicine (Wolters Kluwer Health, Inc.) · 2024 · n=69884 · -28.13 mL mean difference in blood loss vs oxytocin at 24 h, n=7403, p=0.020HumanACarbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 Compass PWS Study.Clinical therapeutics · 2026 · n=175 · Treatment difference 0.3 (95% CI: -1.8, 2.4; P = 0.79)HumanAThe Prophylactic Role of Tranexamic Acid in Reducing Blood Loss During Cesarean Delivery: A Prospective Randomized Controlled Trial.Cureus · 2025 · n=300 · Mean EBL in TXA group was 460.33 mL vs 511.93 mL in placebo group, p < 0.05.Human